General Announcement::Company Statement

Issuer & Securities

Issuer/ Manager
BIOCON BIOLOGICS GLOBAL PLC
Securities
BIOCONBIO US$800M6.67%N291009A - US090978AA56 - RJUB
BIOCONBIO US$800M6.67%N291009R - USG11185AA61 - KSEB
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
07-Jul-2025 11:02:28
Status
New
Announcement Sub Title
Company Statement
Announcement Reference
SG250707OTHRF3I5
Submitted By (Co./ Ind. Name)
Biocon Biologics Limited / Akhilesh Nand
Designation
Company Secretary
Effective Date and Time of the event
07/07/2025 08:30:00
Description (Please provide a detailed description of the event in the box below)
Biocon Biologics Receives MHRA UK Approval for Vevzuo and Evfraxy , Denosumab Biosimilars.

Attachments

BBL_SGX_MHRA_Deno_07072025.pdf
Total size =367K